Novo Nordisk A/S $NVO is Lind Value II ApS’s 8th Largest Position

Lind Value II ApS lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 451.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 84,225 shares of the company’s stock after acquiring an additional 68,939 shares during the quarter. Novo Nordisk A/S makes up 2.6% of Lind Value II ApS’s portfolio, making the stock its 8th biggest holding. Lind Value II ApS’s holdings in Novo Nordisk A/S were worth $5,813,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of NVO. North Capital Inc. purchased a new position in Novo Nordisk A/S in the first quarter valued at about $27,000. Stone House Investment Management LLC acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $30,000. Disciplina Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 297 shares during the last quarter. Dagco Inc. acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $37,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $49.40 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The company has a fifty day simple moving average of $56.17 and a 200 day simple moving average of $61.92. The company has a market cap of $220.58 billion, a P/E ratio of 13.57, a P/E/G ratio of 2.33 and a beta of 0.68. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $113.02.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s payout ratio is presently 22.53%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NVO. Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. Morgan Stanley lowered shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and dropped their price target for the stock from $59.00 to $47.00 in a research note on Monday, September 29th. Weiss Ratings restated a “hold (c)” rating on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. Jefferies Financial Group initiated coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating for the company. Finally, BMO Capital Markets reiterated a “market perform” rating and issued a $55.00 price objective (up from $50.00) on shares of Novo Nordisk A/S in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $76.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.